Sclerostin (SOST) is an extracellular Wnt signaling antagonist which negatively regulates bone mass.
Introduction
Sclerostin (SOST) is an extracellular Wnt signaling antagonist with high endogenous expression in osteocytes(1, 2). Human disorders of SOST expression and activity result in bone overgrowth in rare autosomal recessive syndromes, including sclerosteosis and Van Buchem disease. SOST is well described to negatively regulate osteogenesis and bone mass(1, 2), and targeted Sost deletion in mice results in a high BMD phenotype with increased bone strength (3) . Consequently, significant interests exist in the use of anti-SOST neutralizing antibodies for the clinical entity of osteoporosis, such as romosozumab (AMG 785, Amgen Inc., Thousand Oaks, CA)(4-6) and blosozumab (LY2541546, Eli Lilly and Company, Indianapolis, IN). Preclinical studies have shown that anti-Sost antibodies inhibit bone loss in ovariectomy (7, 8) , in the aged skeleton, and during fracture healing (9, 10) . The expression and function of SOST in skeletal tumors remains poorly understood.
The importance of avoiding tumorigenesis cannot be overlooked in the field of osteoporotic therapies. This issue has growing importance with protein-based bone anabolism. For example, the main FDA approved recombinant protein for local bone formation is BMP2 (Bone Morphogenetic Protein 2).
BMP ligands and BMP receptors are expressed in most osteosarcoma (OS) cell lines and OS subtypes.
Moreover, although disagreement in the literature exists, the presence of BMP signaling in OS may impart a worse prognosis (11) . On the cellular level, BMP signaling appears to mediate pro-migratory effects in both OS and chondrosarcoma (CS) cell types. Likewise, Parathyroid Hormone (PTH) is the main FDA approved anabolic agent in the treatment of osteoporosis. Unfortunately, the clinical duration of use for PTH is limited to 24 months, owing to the potential risk of osteosarcomagenesis (as documented in rat studies) (12) . Thus, currently approved agents for bone anabolism are not without potential risks for skeletal sarcomagenesis.
There is to date little known regarding SOST expression and function in skeletal sarcomas.
Several pieces of data suggest that SOST has diverse roles in epithelial malignancies, including breast carcinoma, prostate carcinoma, thyroid carcinoma, and renal cell carcinoma. In general, studies have demonstrated that overexpression of numerous Wnt components in OS (including Wnt ligands, Frizzled,
and LRP receptors), highlighting the implications of aberrant Wnt/β-catenin signaling in OS progression (13, 14 (18) . Despite this, the expression and function of SOST in skeletal tumors is poorly understood. Here, we provide a comprehensive description of SOST expression in skeletal bone-and cartilage-forming tumors.
Materials and Methods

Antibodies and reagents
Primary antibodies used in this study were anti-SOST (ab75914, Abcam). All other reagents were purchased from Dako unless otherwise specified.
Tissue Procurement
Tumors were retrospectively collected from biopsy and resection specimens at the University of California, Los Angeles under IRB# 13-897. Each tumor was re-examined by two blinded bone tissue pathologists to ensure accuracy of original diagnosis. When appropriate, radiographs were also examined to confirm concordance with the pathologic diagnosis. Demographic features and specific tumor measurements were recorded, including patient age, gender, anatomic location, tumor size, and history of neoadjuvant therapy (Supplementary Table 1 ). When available, undecalcified samples were chosen for 
Histological and immunohistochemical analyses
Five-micron-thick paraffin sections of bone and cartilage tumors were stained with haematoxylin and eosin (H&E). Using H&E sections, histomorphologic assessments were made to confirm tumor type and to determine characteristics of different regions within each section. Additional sections were analyzed by indirect immunohistochemistry. Briefly, unstained sections were deparaffinized in xylene and a series of graded ethanol solutions, and rehydrated using phosphate buffered solution. The slides were incubated in 3% hydrogen peroxide for 20 min at room temperature to block endogenous peroxidase activity.
0.125% trypsin induced epitope retrieval was performed for 20 min at room temperature, using the Discrepancies in semi-quantification of intensity of staining between observers were found in less than 10% of samples. In this case, the intensity of stain was determined by consensus re-review of the slides by all three observers. Distribution of staining was determined on a continuous 0%-100% scale, estimating the percentage of tumor cells with SOST immunoreactivity in 5% increments. (19) . In addition, SOST and osteogenic marker expression was assayed at serial timepoints under osteogenic differentiation conditions (0, 3, 6, and 9 days). Osteogenic medium included basal medium supplemented with 50 μg/mL ascorbic acid and 3 mmol/L β-glycerophosphate. For RNA expression among primary tumors, samples were snap frozen in liquid nitrogen as soon as possible after surgical removal. Tissue homogenization and RNA extraction was performed as previously described (19) .
Regular PCR and Quantitative RT-PCR
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Statistical analysis
Statistical analysis was performed using an appropriate Student's t-test when two groups of numerical values were being compared, as in the case of staining distribution. A Fisher's exact test was performed to determine statistical significance of contingency tables, as in the case of staining intensity. In general, a p-value less than 0.05 was considered statistically significant.
Results
SOST expression in benign bone tumors
All cases of osteoid osteoma and osteoblastoma demonstrated characteristic anastomosing trabeculae of woven bone, with a single layer of activated osteoblasts and variable multi-nucleated osteoclasts ( Table 1) .
SOST expression in conventional osteosarcoma
Next, SOST immunoreactivity was examined in osteoblastic osteosarcoma (OS) specimens.
Demographic information can be found in Supplementary Table 1 . A wide array of tissue types were examined, including initial biopsies, primary resection, and metastatectomy specimens. 46% of tumors (12/26) were from biopsy or resection samples with no history of chemotherapy or radiation. Results
showed that among osteoblastic OS, SOST expression highly correlated with bone matrix expression Fig. 2A-D) . Across samples, we observed high SOST immunoreactivity in those osteoblastic cells lining and immediately adjacent to bone deposition. This was particularly apparent in samples with chemotherapy induced 'differentiation.' Regular PCR confirmed expression of SOST among osteoblastic OS samples on the gene level (Supplementary Fig. 1 ). Chondroblastic OS samples showed a similar phenomenon with SOST immunoreactivity in and around areas of endochondral ossification ( Fig. 2E-H) .
SOST immunostaining was particularly seen in areas of mineralized cartilage and bone (Fig. 2E,F) , but was also in present in areas without mineralization (Fig. 2G,H) . Finally, subtypes of conventional OS with minimal bone deposition were examined, including fibroblastic OS and giant cell rich OS. These subtypes with minimal bone matrix showed infrequent SOST immunoreactive cells (Fig. 2I ,J, giant cell rich OS shown). In these samples with minimal neoplastic bone, sparse SOST expression was present in osteoblastic cells in and around the bone matrix. Semi-quantification of SOST immunohistochemical staining was variable and reflected the range of bone production among OS samples ( Table 1) To further document the relationship between neoplastic bone matrix and SOST immunohistochemical staining, serial random high magnification images from conventional OS were quantified both for the degree of SOST staining and amount of bone matrix (Fig. 2K) . Briefly, total SOST immunoreactivity per 40x field and total bone matrix per 40x field were quantified using Adobe Photoshop, and each high
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9 magnification image was placed on a scatterplot. Results confirmed a significant correlation between relative SOST immunostaining and bone matrix production (correlation coefficient, R 2 =0.6788). In summary, conventional OS showed a reproducible immunohistochemical staining pattern for SOST, with the degree and localization of stain highly correlated with bone matrix production.
SOST expression in osteosarcoma subtypes
We next sought to examine SOST expression among distinct OS subtypes (including parosteal, periosteal, and telangiectatic OS). Examination of parosteal OS specimens revealed a characteristic dual lineage tumor with alternating zones of bony trabeculae and fibroblastic stroma (Fig. 3A-F) . A relative abundance of SOST immunostaining was observed among parosteal OS samples. Staining of variable intensity was observed in a majority of parosteal tumor cells (1-3+ intensity, 61% of tumor cells).
Notably, SOST expression was observed both in the spindle cell population of fibroblastic areas and also within osteocytes of neoplastic bone (Fig. 3A-F Fig. 2 ). Like conventional OS, SOST immunoreactivity was seen in areas of ossification (2+ staining intensity, not shown). Finally, telangiectatic osteosarcoma specimens were examined which demonstrated a characteristic appearance of highly atypical neoplastic cells in a background of blood, fibrin and sparse bone. Among telangiectatic OS specimens, SOST immunoreactivity was again noted in areas of ossification in the minority of cells (1-3+, 26% of tumor cells). Tumors without bone deposition showed no detectable SOST expression (Fig. 3G,H) . In summary, like conventional OS, most OS variants demonstrate SOST immunoreactivity in and around areas of neoplastic bone. Parosteal OS is the notable exception to this observation, which showed significant SOST expression among both fibrous and osseous components.
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SOST expression among OS cell lines
SOST expression was next assayed across OS cell lines (Fig. 4) . Results showed a wide variation across OS cell lines (>97 fold variation) (Fig. 4A) . Those high expressing SOST cell lines included SJSA, HOS and MNNG. Basal SOST expression did not appear to correlate well with known comparative growth rates, cellular morphology, or metastatic potential (20) (21) (22) (23) (24) (25) (26) .
We next inquired as to whether SOST expression correlated with markers of canonical Wnt signaling or osteogenic differentiation among seven OS cell lines, as assessed by quantitative RT-PCR ( Fig. 4B-F) .
We first inquired as to whether high SOST expression correlated with low Wnt/β-catenin signaling activity, as could be hypothesized from the known functions of SOST as an extracellular Wnt inhibitor ( Fig. 4B-D) . Markers of Wnt/β-catenin signaling used included AXIN2, CYCLIN D, and CMYC (Fig. 4B-D) , with each dot on a scatter plot representing a different OS cell line. Overall, markers of Wnt/β-catenin signaling activity did not correlate well with SOST expression. A line of best fit for each gene correlation to SOST is shown (Fig. 4B-D) . Correlation coefficients were close to zero for all comparisons (R 2 range: 0.04736-0.07395). Next, basal expression of markers of osteogenic differentiation was compared to SOST expression across OS cell lines (Fig. 4E,F) . Of the genes assessed, ALP expression (Alkaline phosphatase, a marker of osteoblastic differentiation) showed a positive correlation with SOST expression, (R 2 =0.46793). In contrast, RUNX2 showed no correlation with SOST expression, (R 2 =0.00255). In aggregate, only the marker of osteogenic differentiation ALP showed a correlation with SOST expression among OS cell lines.
Next, we assayed SOST expression during the osteogenic differentiation of OS cell lines (Fig. 4G,H) . In general, SOST expression has been reported to increase overtime in osteoblastic cell culture. For this purpose, low SOST expressing cell lines (including KHOS312H and G292 lines) were examined under
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11 standard osteogenic conditions from 0-9 days of differentiation. Results showed a significant and time dependent induction of SOST expression with osteogenic conditions across both cell lines examined. The absolute change in SOST expression varied widely (overall 19-and 13,045-fold upregulations for G292
and KHOS312H cells, respectively -a nearly 700 fold difference in absolute change). Next, changes in SOST expression overtime under differentiation conditions were compared to the osteogenic markers RUNX2 and OCN (Supplementary Tables 3,4) . For this purpose, relative SOST expression was normalized to either RUNX2 or OCN expression overtime in osteogenic culture. Overall, the degree of increase in SOST expression was higher than the degree of increase in either osteogenic marker. This was observed in both KHOS312H and G292 cells (Supplementary Tables 3,4) . Overall, SOST expression seemed to correlate with osteogenic gene expression during osteogenic differentiation conditions.
SOST expression in cartilage-forming tumors
Next, SOST expression was compared across benign and malignant cartilage forming tumors (Fig. 5) .
All tumors showed some degree of SOST immunoreactivity in the minority of tumor cells (17/17 samples, Table 1 
Discussion
In brief, the present study has identified several unique features of SOST in skeletal tumors.
First, SOST expression is present to some degree across nearly all bone-and cartilage-forming skeletal tumors. Second, the distribution of SOST among OS tumors correlated highly with neoplastic bone deposition, while among CS specimens a correlation with any histopathologic features was not observed. antibody selection, and variable tissue processing may well explain these discrepancies between our two studies.
In vitro
The expression of SOST in OS and CS raises intriguing questions regarding its role in the basic function in skeletal sarcoma tumor biology. The role of other Wnt signaling antagonists has been explored in OS and CS, including WIF-1, SFRP3, and DKK1. In general, numerous Wnt signaling components have been described as upregulated among OS and CS tumors (13, 14, 27 ) (although this is not entirely agreed upon in the literature (28)), while Wnt antagonists such as WIF1 and SFRP3 are generally reduced (15) (16) (17) . In contrast, DKK1 appears to be upregulated in OS, both locally and
systemically (29) . In CS, DKK1 overexpression when combined with increased Wnt signaling activity portends a worse clinical outcome (18) . Our data clearly localize SOST to OS cells with osteoblastic differentiation. This is not unlike its native expression in osteocytes, and a potential role for SOST in repressing bone formation in OS is a reasonable hypothesis given its distribution. In cartilaginous tumors, the role of SOST is less clear based on its patchy expression pattern, which in our hands did not correlate well with areas of mineralization or myxoid change. Importantly, simple detection of SOST in human cell lines and human skeletal tumors does not necessarily imply retained bioactivity. It is intriguing, however, to link the overproduction of SOST in OS tumors to the high incidence of osteoporosis among long term surviving OS patients (30, 31) . However, osteoporosis among this patient population is no doubt multifactorial, with contributing factors including exposure to chemotherapeutic agents, poor nutrition, and decreased physical activity. At this point, the potential link between SOST overproduction and osteoporosis among OS patients is a theoretical one. 
Concluding Remarks
The present study highlights the presence of SOST across benign and malignant bone-and cartilageforming skeletal tumors. SOST strongly localizes to areas of osteoblastic differentiation and ossification. 
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